FDA 483 - G21 USA, Inc. - July 25, 2023

An FDA inspection of G21 USA, Inc., an initial importer in New York, revealed significant deficiencies in their quality system. The firm lacked adequate procedures for handling customer complaints, implementing corrective and preventive actions, and documenting personnel training. These issues indicate a need for comprehensive improvements in their operational controls.